Navigation Links
Universitat Autonoma de Barcelona researchers first to clone mice in Spain
Date:6/12/2009

ng process. Nuno Costa-Borges, Josep Santal and Elena Ibez are studying whether the use of valproic acid could contribute to an increase in the success rate of nuclear transfer cloning, currently situated at approximately 1% for mice using standard procedures.

Valproic acid is an inhibitor of the enzyme histone deacetylase, located at the cell nucleus where the DNA is found. Research carried out until now has shown that histone deacetylase inhibitors seem to contribute to an increase in levels of gene expression, which would favour the reprogramming of the somatic cell nucleus transferred to the oocyte cytoplasm. Its use in nuclear transfer processes however is very recent. It was first used two years ago and research until now has focused on trichostatin, an inhibitor which has significantly improved the efficiency of mouse cloning, raising it to 5%.

Studies carried out by researchers at UAB can not only be applied to reproductive cloning of animal models; they can also be used for the reprogramming of cells for therapeutic aims.

Costa-Borges, Santal and Ibez are comparing three groups of cloned embryos in their research: valproic acid in the first group, trichostatin in the second and no inhibiting substance in the third group. The three mice in this case were cloned using the first (Cloe and Clona) and second (Cleo) inhibitors. In vitro experiments already pointed to improvements in the development of cloned embryos using inhibitors. However, scientists must wait until the end of the in vivo test period in July to obtain more conclusive data.


'/>"/>

Contact: Maria Jesus Delgado
MariaJesus.Delgado@uab.cat
34-935-814-049
Universitat Autonoma de Barcelona
Source:Eurekalert

Page: 1 2

Related biology news :

1. IRB Barcelona to coordinate two European projects on biomedicine
2. Researchers at IRB Barcelona produce more data on key genes in diabetes
3. Barcelona Declaration 2008: Challenges and Pathways to Earth Sustainability
4. Protein that triggers plant cell division revealed by researchers
5. Researchers create freestanding nanoparticle films without fillers
6. Researchers identify new risk factor gene for rheumatoid arthritis
7. Researchers shed light on trading behavior in animals -- and humans
8. University of Saskatchewan and Canadian Synchrotron researchers shed light on esophageal disease
9. Faculty of Translational Medicine boosts support for biomedical researchers
10. USC researchers present diabetes findings at American Diabetes Association Scientific Sessions
11. MSU researchers receive $400,000 in first wave of stimulus funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
(Date:7/30/2014)... until they hatched 4.5 years later, according to a ... PLOS ONE by Bruce Robison from Monterey ... have a single reproductive period during their life, where ... eggs until they hatch. Shallow-water octopuses typically care for ... is known about the brooding of deep-sea species. Using ...
(Date:7/30/2014)... (ACS) announced today that David L. Kaplan, Ph.D., will ... & Engineering as editor-in-chief. With the first issue ... will feature high-quality research in the rapidly burgeoning field ... materials that interact with living or biological systems. , ... tremendous growth in the field of biomaterials over the ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... "Environmental Nanoparticles: Science, Ethics & Policy" on Nov. ... Center in Newark, Del. The registration deadline is ... co-sponsored by UD,s Center for Critical Zone Research ... will include presentations by nationally and internationally recognized ...
... the first critical steps in unraveling the mysteries of ... that afflicts 500,000 people worldwide each year and nearly ... An international team led by Murat Gunel, professor ... and chair of genetics, and a Howard Hughes Medical ...
... Conn. If climate disasters are to be averted, atmospheric carbon ... today, according to a study published in Open Atmospheric ... the United States, the United Kingdom and France. ... a planet similar to that on which civilization developed, an optimum ...
Cached Biology News:Workshop on environmental nanoparticles at UD, Nov. 10-11 2Yale researchers unravel mystery of brain aneurysms 2Revised theory suggests carbon dioxide levels already in danger zone 2
(Date:7/30/2014)... MARLBOROUGH, Mass. , July 30, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... study (RXI-109-1402) with RXI-109, for the reduction ... scar revision surgery, has been initiated. ...
(Date:7/30/2014)... Vala Sciences was recently awarded ... Agency (EPA). This new contract was awarded for ... tests designed to assess the effect of chemical ... connections between neurons (synapses), which are critical for ... by environmental pollutants likely contributes to a variety ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 LayerBio, ... announces completion of its first round of seed financing ... will enable preliminary efforts to develop a novel sustained-release ... support of our investors and their commitment to this ... of LayerBio. "Ophthalmology is one of many areas in ...
(Date:7/29/2014)... of significant technological challenges in their quest to ... for the James Webb Space Telescope. , The ... scientist at NASA,s Goddard Space Flight Center in ... arrays that is, those activated by applying ... the current technology,s magnetically activated arrays. This advance ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... When ... has made a lasting impact on both agriculture and weed science around the globe. He ... techniques to benefit farmers. Thousands of students have followed in his footsteps and are now making ... ...
... results of this study will be presented during the ... June 3, 2009 COLUMBIA, Md., May 30 Lead ... from the University of Miami , evaluated whether ... determining rejection or infection in kidney transplant recipients. Patients ...
... and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of a Phase 1 trial presented during an oral ... Annual Meeting. Preliminary results as of April 2009 showed ... addition, OGX-427 demonstrated declines in circulating tumor cells at ...
Cached Biology Technology:Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 2Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 3Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science 4Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 2OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 3OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 4OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial 5